Letter | Published:

Structural basis for molecular recognition of folic acid by folate receptors

Nature volume 500, pages 486489 (22 August 2013) | Download Citation

This article has been updated


Folate receptors (FRα, FRβ and FRγ) are cysteine-rich cell-surface glycoproteins that bind folate with high affinity to mediate cellular uptake of folate. Although expressed at very low levels in most tissues, folate receptors, especially FRα, are expressed at high levels in numerous cancers to meet the folate demand of rapidly dividing cells under low folate conditions1,2,3. The folate dependency of many tumours has been therapeutically and diagnostically exploited by administration of anti-FRα antibodies, high-affinity antifolates4,5, folate-based imaging agents and folate-conjugated drugs and toxins6,7,8. To understand how folate binds its receptors, we determined the crystal structure of human FRα in complex with folic acid at 2.8 Å resolution. FRα has a globular structure stabilized by eight disulphide bonds and contains a deep open folate-binding pocket comprised of residues that are conserved in all receptor subtypes. The folate pteroate moiety is buried inside the receptor, whereas its glutamate moiety is solvent-exposed and sticks out of the pocket entrance, allowing it to be conjugated to drugs without adversely affecting FRα binding. The extensive interactions between the receptor and ligand readily explain the high folate-binding affinity of folate receptors and provide a template for designing more specific drugs targeting the folate receptor system.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 21 August 2013

    Atomic distances in Fig. 3a and the main text were corrected; the primary PDB accession code was corrected.


Primary accessions

Protein Data Bank

Data deposits

The structure of FRα bound to folic acid has been deposited in the Protein Data Bank under the accession code 4LRH.


  1. 1.

    The role of folate receptor α in cancer development, progression and treatment: cause, consequence or innocent bystander? Int. J. Cancer 119, 243–250 (2006)

  2. 2.

    et al. Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human-cells. J. Clin. Invest. 81, 1398–1406 (1988)

  3. 3.

    et al. Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate. Proc. Natl Acad. Sci. USA 89, 6006–6009 (1992)

  4. 4.

    Anticancer antifolates: current status and future directions. Curr. Pharm. Des. 9, 2593–2613 (2003)

  5. 5.

    et al. Synthesis and biological activity of a novel series of 6-substituted thieno 2,3-d pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. J. Med. Chem. 52, 2940–2951 (2009)

  6. 6.

    & Folate-targeted chemotherapy. Adv. Drug Deliv. Rev. 56, 1127–1141 (2004)

  7. 7.

    et al. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol. Pharm. 4, 659–667 (2007)

  8. 8.

    et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 67, 4434–4442 (2007)

  9. 9.

    & Folate metabolism and requirements. J. Nutr. 129, 779–782 (1999)

  10. 10.

    Physiology of folate and vitamin B12 in health and disease. Nutr. Rev. 62, S3–S12; discussion S13. (2004)

  11. 11.

    , & Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Exp. Rev. Mol. Med. 11, e4 (2009)

  12. 12.

    The biological chemistry of folate receptors. Blood 79, 2807–2820 (1992)

  13. 13.

    et al. A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis. J. Biol. Chem. 284, 4267–4274 (2009)

  14. 14.

    & Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev. 56, 1067–1084 (2004)

  15. 15.

    et al. Glycoprotein structural genomics: solving the glycosylation problem. Structure 15, 267–273 (2007)

  16. 16.

    Crystal structure of chicken riboflavin-binding protein. EMBO J. 16, 1475–1483 (1997)

  17. 17.

    & in Folic Acid Metabolism in Health and Disease (ed. Picciano, M. F.) 91–120 (Wiley, 1990)

  18. 18.

    , & Folate-mediated drug delivery: effect of alternative conjugation chemistry. J. Drug Target. 7, 157–169 (1999)

  19. 19.

    Experimental phasing with SHELXC/D/E: combining chain tracing with density modification. Acta Crystallogr. D 66, 479–485 (2010)

  20. 20.

    dm: an automated procedure for phase improvement by density modification. Joint CCP4 and ESF-EACBM Newsletter on Protein Crystallography 31, 34–38 (1994)

  21. 21.

    & Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004)

  22. 22.

    , & Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240–255 (1997)

  23. 23.

    & in Methods in Enzymology Vol. 276 (eds Carter, C.W. Jr. & Sweet, R. M.) 307–326 (Academic, 1997)

  24. 24.

    XDS. Acta Crystallogr. D 66, 125–132 (2010)

  25. 25.

    The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760–763 (1994)

  26. 26.

    et al. Structures from anomalous diffraction of native biological macromolecules. Science 336, 1033–1037 (2012)

  27. 27.

    et al. Decision-making in structure solution using Bayesian estimates of map quality: the PHENIX AutoSol wizard. Acta Crystallogr. D 65, 582–601 (2009)

  28. 28.

    et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 338, 284–293 (2005)

Download references


We thank Y. Jones for the pHL-Fc plasmid and H. L. Monaco for providing the chicken riboflavin-binding protein coordinates. The atomic coordinates have been deposited in the Protein Data Bank with accession codes listed in Supplementary Table 1. We thank staff members of the Life Science Collaborative Access Team of the Advanced Photon Source (APS) for assistance in data collection at the beam lines of sector 21, which is in part funded by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (Grant 085P1000817). Use of APS was supported by the Office of Science of the US Department of Energy, under contract no. DE-AC02-06CH11357. This work was supported by the Jay and Betty Van Andel Foundation, and work by the Yong, Xu and Melcher laboratories is supported by the American Asthma Foundation, Ministry of Science and Technology (China) grants 2012ZX09301001-005 and 2012CB910403, Amway (China), by National Institutes of Health grants R01 DK071662 (H.E.X.) and R01 GM102545 (K.M.), and by the National Research Foundation Singapore under its Clinician Scientist Award NMRC/CSA/026/2011 (E.-L.Y.). C.C. is recipient of the NUS Graduate School for Integrative Sciences and Engineering Scholarship.

Author information

Author notes

    • Chen Chen
    •  & Jiyuan Ke

    These authors contributed equally to this work.


  1. Program for Structural Biology and Drug Discovery, Van Andel Research Institute, 333 Bostwick Avenue North East, Grand Rapids, Michigan 49503, USA

    • Chen Chen
    • , Jiyuan Ke
    • , X. Edward Zhou
    • , H. Eric Xu
    •  & Karsten Melcher
  2. National University of Singapore Graduate School for Integrative Science and Engineering, National University of Singapore, Singapore 117456, Singapore

    • Chen Chen
  3. VARI/SIMM Center, Center for Structure and Function of Drug Targets, CAS-Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    • Wei Yi
    •  & H. Eric Xu
  4. Life Sciences Collaborative Access Team, Synchrotron Research Center, Northwestern University, Argonne, Illinois 60439, USA

    • Joseph S. Brunzelle
  5. Department of Obstetrics & Gynecology, National University Hospital, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore

    • Jun Li
    •  & Eu-Leong Yong


  1. Search for Chen Chen in:

  2. Search for Jiyuan Ke in:

  3. Search for X. Edward Zhou in:

  4. Search for Wei Yi in:

  5. Search for Joseph S. Brunzelle in:

  6. Search for Jun Li in:

  7. Search for Eu-Leong Yong in:

  8. Search for H. Eric Xu in:

  9. Search for Karsten Melcher in:


E.-L.Y., J.L., J.K., H.E.X. and K.M. conceived the project and designed research. C.C., J.K., X.E.Z., W.Y. and J.S.B. performed research. C.C., J.K., H.E.X. and K.M. wrote the paper with contributions from all authors.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to H. Eric Xu or Karsten Melcher.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains Supplementary Figures 1-9 and Supplementary Table 1. Supplementary Table 1 was added on 01 August 2013.

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.